5th Symposium on ATP1A3 in Disease
UCL Institute of Neurology, London, UK
24th-26th August 2016
Final Draft Symposium Timetable

Meeting agenda
Morning session 25th Theme: Clinical developments in ATP1A3-related disease
Afternoon session 25th Theme: Research developments in ATP1A3-related disease
Morning session 26th Theme: Translation to Treatments in ATP1A3-related disease

Clinical developments in ATP1A3-related disease

Chairs: Helen Cross and Mohamad Mikati

- 0900 Plenary Introduction. Allison Brashear, Professor and Chair of Neurology, Wake Forest University School of Medicine Winston Salem, NC USA.
  Where we are in ATP1A3-related disease today?

- 0945 Diane Doummar, Paris, France: Encephalopathies associated with ATP1A3 mutation
- 1000 Hendrick Rosewich, Göttingen, Germany. CAPOS
- 1015 Madeleine Scharf, Hannover, Germany: Neuronal Na+/K+ ATPase as an autoantibody target in paraneoplastic neurologic syndrome.

1030-1100 Coffee Break

Chairs: Hendrik Rosewich and Sanjay Sisodiya

1100-1230 What are the clinical events in ATP1A3-related disease?
- A video and clinical panel session to discuss events that are seizures confirmed on EEG recording, those that are hemiplegic episodes and that are undiagnosed.

- Expert panel: murine experts (Steve Clapcote, Leeds, UK; Mohamad Mikati, Duke, USA), human epilepsy (Mohamad Mikati, Duke, USA; Helen Cross, GOSH, London; Beate Diehl, UCLH, UK; Alexis Arzimanoglou, Lyon, France), human movement disorders (Kailash Bhatia, UCL and Lucinda Carr, GOSH, London).

- Intended outcome: consensus definitions of events in AHC, key for therapy trials.

1230-1430 Lunch in Foyer with poster session
Research developments in ATP1A3-related disease

Chairs: Erin Heinzen, New York, USA and Steve Clapcote, Leeds, UK

1430-1800

- Arn van den Maagdenberg, Leiden, Netherlands: AHC Gene 2 – an update
- Jennifer Kearney, Chicago, US: Genetic modifiers for ATP1A3
- David Goldstein, New York, US: Multi-electrode array work update
- Bente Vilsen, Aarhus, Denmark: Ion concentrations, ATP1A3 mutation & disease, and rostafuroxin

Coffee Break

- Hugh Piggins, Manchester, UK: Disrupted Daily and Circadian rhythms in the Myshkin Mouse Model of Mania
- Minako Hoshi, Kyoto, Japan: ATP1A3 as target of beta-amyloid assembly
- Ronald Melki, Paris, France: α-synuclein interaction with α3-Na+/K+-ATPase and relation to decline?
- Jan Koenderink, Nijmegen, The Netherlands: Biochemical and electrophysiological analysis of ATP1A3 mutations

Conference Dinner, London

Translation to Treatments in ATP1A3-related disease

Chairs Sanjay Sisodiya, UCL, UK and Tsveta Schyns, ENRAH, Belgium

0900-0945 Plenary: Francesco Muntoni, GOSH, London UK
Gene therapy in a neurological disease, the journey: Duchenne Muscular Dystrophy,

0945. Natalya Fedosova, Aarhus, Denmark: On the way to isoform – specific drugs
1000. Steve Clapcote, Leeds, UK: Gene therapy in ATP1A3 models and decanoic acid in animal models
1015. Emmanuel Flamand-Roze, Paris, France: Sharing the experience of a clinical trial in alternating hemiplegia

1030-1100 Coffee Break

1100. Helen Cross, London, UK: Decanoic acid in humans and experience of KD in AHC
1130. Elisa de Grandis, Genoa, Italy: Flurarizine and AEDs – where are we now?
1200. Juan Kaski, London, UK: Cardiac involvement in AHC: treatment beyond the brain?

CONCLUSIONS and End of Meeting Lunch